Compare TYRA & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | ZD |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 1999 |
| Metric | TYRA | ZD |
|---|---|---|
| Price | $33.86 | $43.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $47.50 | $39.71 |
| AVG Volume (30 Days) | ★ 997.4K | 462.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.15 |
| Revenue | N/A | ★ $1,364,028,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.16 |
| P/E Ratio | ★ N/A | $39.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.75 | $22.45 |
| 52 Week High | $40.65 | $50.55 |
| Indicator | TYRA | ZD |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 44.45 |
| Support Level | $33.81 | $34.96 |
| Resistance Level | $33.99 | $45.26 |
| Average True Range (ATR) | 2.25 | 1.73 |
| MACD | -0.28 | -0.55 |
| Stochastic Oscillator | 16.55 | 9.81 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.